Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis
- PMID: 38873345
- PMCID: PMC11170162
- DOI: 10.1016/j.nmni.2024.101437
Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis
Abstract
Introduction: The surge of multidrug-resistant TB (MDR-TB) in Iran poses a significant challenge to global healthcare. The introduction of delamanid (DLM) and bedaquiline (BDQ), two potent antimycobacterial drugs, marks a crucial advance. Nevertheless, as resistance in Mycobacterium tuberculosis is on the rise in Iran and resistance to these newer medications is emerging, investigations in this field are of utmost importance.
Methods: In this cross-sectional study, 38 MDR-TB strains were collected from five distinct regional TB laboratories in Iran. The clinical isolates were confirmed as M. tuberculosis using the phenotypic tests and IS6110-based PCR assay. Drug susceptibility testing (DST) for isoniazid, rifampicin, ethambutol, DLM, and BDQ was performed using WHO-approved methods. Sequencing was used to investigate genetic mutations in DLM (ddn, fgd1) and BDQ (Rv0678, atpE, pepQ) genes associated with resistance.
Results: Among the 38 collected MDR-TB isolates, 7 (18.5 %) exhibited resistance to DLM, while all remained susceptible to BDQ. Analysis of the sequencing data revealed that the ddn gene exhibited the highest number of mutations in DLM-resistant isolates, including 18 nonsynonymous mutations and 1 indel leading to frameshift mutations. A common mutation, Gly81Ser, was present in 4 of the DLM-resistant isolates (4/7; 57.1 %). A synonymous mutation, T960C, in the fgd1 gene was uniformly found in DLM-resistant samples. Notably, no significant mutations were observed in the atpE, Rv0678, or pepQ genes in any of the BDQ-susceptible isolates.
Conclusions: Our study underscores the emergence of DLM resistance in a subset of MDR-TB isolates in Iran, primarily associated with mutations in the ddn gene. This emphasizes the ongoing necessity for TB drug resistance surveillance and research. While BDQ remains efficacious, the emergence of DLM resistance is a concerning development, warranting further exploration into resistance mechanisms and the formulation of effective TB control strategies.
Keywords: Antimicrobial resistance; Bedaquiline; Delamanid; Multidrug-resistance; Mycobacterium tuberculosis.
© 2024 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.J Clin Lab Anal. 2024 Aug;38(15-16):e25091. doi: 10.1002/jcla.25091. J Clin Lab Anal. 2024. PMID: 39431709 Free PMC article. Review.
-
Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid.Antibiotics (Basel). 2020 Mar 23;9(3):133. doi: 10.3390/antibiotics9030133. Antibiotics (Basel). 2020. PMID: 32209979 Free PMC article. Review.
-
Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.J Clin Microbiol. 2020 Oct 21;58(11):e01304-20. doi: 10.1128/JCM.01304-20. Print 2020 Oct 21. J Clin Microbiol. 2020. PMID: 32907992 Free PMC article.
-
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.Sci Rep. 2021 Sep 30;11(1):19431. doi: 10.1038/s41598-021-98862-4. Sci Rep. 2021. PMID: 34593898 Free PMC article.
-
Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan.BMC Microbiol. 2022 Feb 25;22(1):62. doi: 10.1186/s12866-022-02475-4. BMC Microbiol. 2022. PMID: 35209842 Free PMC article.
Cited by
-
Analysis of non-tuberculous mycobacteria types in high tuberculosis endemic areas.J Health Popul Nutr. 2025 Feb 28;44(1):54. doi: 10.1186/s41043-025-00765-x. J Health Popul Nutr. 2025. PMID: 40022224 Free PMC article.
-
Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran.BMC Microbiol. 2025 Aug 15;25(1):509. doi: 10.1186/s12866-025-04213-y. BMC Microbiol. 2025. PMID: 40817101 Free PMC article.
-
Risk of tuberculosis disease in patients receiving TNF-α antagonist therapy: A meta-analysis of randomized controlled trials.New Microbes New Infect. 2024 Nov 16;62:101533. doi: 10.1016/j.nmni.2024.101533. eCollection 2024 Dec. New Microbes New Infect. 2024. PMID: 39639969 Free PMC article. Review.
References
-
- Nasiri M.J., Dabiri H., Darban-Sarokhalil D., Rezadehbashi M., Zamani S. Prevalence of drug-resistant tuberculosis in Iran: systematic review and meta-analysis. Am J Infect Control. 2014;42(11):1212–1218. - PubMed
-
- World Health Organization (WHO) operational handbook on tuberculosis . 2022. Module 4: treatment-drug-resistant tuberculosis treatment.
-
- Caminero J.A., Sotgiu G., Zumla A., Migliori G.B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621–629. - PubMed
LinkOut - more resources
Full Text Sources